BioSpace News Archive

Theratechnologies Inc. today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.

Erasca, Inc. (Nasdaq: ERAS) today announced four poster presentations at the 34th EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics taking place October 26-28 in Barcelona, Spain.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced that its Investigational New Drug (IND) application for belapectin in combination with a checkpoint inhibitor for the treatment of Head and Neck cancer has been filed with the U.S. Food and Drug Administration (FDA) Oncology division.

PDS Biotechnology Corporation announced it will host a Head and Neck Cancer Key Opinion Leader Roundtable for analysts, investors, and the scientific community from 8:30 – 9:30 AM ET on Wednesday, October 26, 2022.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO).

VBI Vaccines Inc. and Agenus announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal antibody targeting the programmed death receptor-1 protein, in primary glioblastoma patients as part of the adaptive platform trial, INSIGhT.

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced additional preclinical data from its pan beta-coronavirus vaccine program, which aims to protect against all SARS-CoV-2 variants of concern and potential future strains belonging to the beta-coronavirus family.

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of an oral presentation at the upcoming 29th International Society of Hypertension (ISH) 2022 conference taking place October 12-16, 2022 in Kyoto, Japan.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief medical officer Dr. Robert O. Dillman will deliver a keynote at the second annual Vaccines Summit 2022 meeting.

Mirati Therapeutics, Inc. (Nasdaq: MRTX), and Aadi Bioscience, Inc. (Nasdaq: AADI), today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors.